DL
Therapeutic Areas
Persica Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PP353 | Chronic Low Back Pain (cLBP) with Modic changes | Phase 2 |
Leadership Team at Persica Pharmaceuticals
DE
Dr. Eddy Littler
Executive Chair of the Board
DW
David Watson
Chief Executive Officer
DD
Dr. Duncan McHale
Chief Medical Officer